Date/Time: Monday, October 18, 2021 - 7:45 PM – 8:45 PM
Log in to Add to My Schedule

Description:

This session will provide an overview of the current state of WGS and transcriptomics for neurological disorders and discuss the impact results can have on clinical management and long-term outcomes. The presenters will review interim data from an observational study that implemented WGS as a first-tier test in patients with leukodystrophy and provide an overview of the next phase of that study which will evaluate clinical utility up to six months after results.

Speakers:

• Kayla J. Muirhead, MS, LCGC; Children’s Hospital of Philadelphia
• Holly Snyder, MS, LCGC; Illumina, Inc.
• Ryan Taft, PhD; Illumina, Inc.